GILD vs NVS: Gilead Sciences and Novartis AG ADR compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Novartis AG ADR is the larger company, worth $275.6B, about 1.5 times Gilead Sciences.
- On earnings, Novartis AG ADR is the cheaper stock (20.1x vs 20.2x).
- Gilead Sciences's price assumes faster free cash flow growth: about 5% a year, against 4% for Novartis AG ADR (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | GILD | NVS |
|---|---|---|
| Market cap | $184.1B | $275.6B |
| Share price | $151.17 | $143.75 |
| Revenue (last fiscal year) | $29.4B | — |
| Free cash flow (last fiscal year) | $9.5B | $15.2B |
| Revenue growth, last year | +10.2% | — |
| Revenue growth per year, last 5 fiscal years | +1.9% | — |
| Operating margin | -8.2% | — |
| Net margin | -10.6% | — |
| Return on equity | -27.4% | 33.3% |
| P/E (trailing) | 20.2x | 20.1x |
| Price / free cash flow | 19.5x | 15.6x |
| EV / EBITDA | — | 14.2x |
| FCF growth the price implies | 4.6% | 3.7% |
| Dividend yield | 2.2% | 3.3% |
| Debt / equity | 3.18x | 1.48x |
| Fundamental grade | D | B |
| Superinvestors holding it | 7 | 12 |
| Insider purchases, last 12 months | 4 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Gilead Sciences
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $27.3B | $10.8B | 36.3% |
| 2022 | $27.3B | $8.3B | 26.9% |
| 2023 | $27.1B | $7.4B | 28.0% |
| 2024 | $28.8B | $10.3B | 5.8% |
| 2025 | $29.4B | $9.5B | 34.0% |
Novartis AG ADR
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | — | $12.5B | — |
| 2022 | — | $12.0B | — |
| 2023 | — | $11.7B | — |
| 2024 | — | $13.8B | — |
| 2025 | — | $15.2B | — |
Where the revenue comes from
Gilead Sciences · by products, 2025
Biktarvy$14.3B49%
Descovy$2.8B9%
Genvoya$1.5B5%
Yescarta$1.5B5%
Trodelvy$1.4B5%
Sofosbuvir/Velpatasvir$1.3B4%
Novartis AG ADR
No segment breakdown reported.
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open GILD in InvestinglyQuestions
Which is bigger, Gilead Sciences or Novartis AG ADR?
Novartis AG ADR (NVS), at $275.6B against $184.1B.
Is GILD or NVS cheaper?
By trailing P/E, Novartis AG ADR (20.1x) is cheaper than Gilead Sciences (20.2x). A lower multiple can also mean the market expects less growth.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.